Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1,2,3 Latest findings presented at the European Society of Cardiology (ESC) Congress 2022 add to the wealth of edoxaban data reinforcing its safety and […]

Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional […]